Contraception
With all patients, especially adolescents, young men, postpartum women, and perimenopausal women, advise about adequate contraception when opportunities arise.
In patients using specific contraceptives, advise of specific factors that may reduce efficacy (e.g., delayed initiation of method, illness, medications, specific lubricants).
In aiding decision-making to ensure adequate contraception:
Look for and identify risks (relative and absolute contraindications).
Assess (look for) sexually transmitted disease exposure.
Identify barriers to specific methods (e.g., cost, cultural concerns).
Advise of efficacy and side effects, especially short-term side effects that may result in discontinuation.
In patients using hormonal contraceptives, manage side effects appropriately (i.e., recommend an appropriate length of trial, discuss estrogens in medroxyprogesterone acetate [Depo–Provera]).
In all patients, especially those using barrier methods or when efficacy of hormonal methods is decreased, advise about post-coital contraception.
In a patient who has had unprotected sex or a failure of the chosen contraceptive method, inform about time limits in post-coital contraception (emergency contraceptive pill, intrauterine device).
Contraceptive visit
History
Menstrual
Obstetrical
Gynecological
Sexual
Partners
Practices
Protection from STIs
Past history of STIs
Prevention of pregnancy
PMH
Meds, All
Habits
Screening for contraindications
Discuss STI risks and screening
Encourage barrier contraception not only for STI but as a back-up for suboptimal adherence
Explore contraceptive choice and adherence (in context of individual's behaviour and risks)
Timeframe for desired pregnancy
Preferences, spontaneity
Typical use failure rates (see below for image) and importance of consistent correct contraceptive use
Barrier (Condom) - 18% failure rate
Combined oral contraceptive pill - 9%
Progestin-only pill (Micronor) - 9%
Side effects: Irregular bleeding
Combined transdermal patch (Evra 1 patch per week x 3 weeks, one week off) - 9%
Stays on even in water, apply to dry clean area excluding breast
17% skin reaction
Combined vaginal ring (NuvaRing x 3 weeks, one week off) - 9%
May remove for 3h (eg. during coitus)
5% vaginitis, leukorrhea
Injectable progestins (DMPA- Depo–Provera 150mg IM q12w) - 6%
Side effects: Irregular bleeding, weight gain, decrease bone density
Consider supplemental low-dose estrogen to reduce irregular bleeding if persists past 3 cycles
Intrauterine devices (LNG-IUD Mirena q7y, CU-IUD q10y) <0.1%
44% amenorrhea at 6 months
Risk of expulsion/perforation postpartum until 6 weeks
Subdermal implant (Nexplanon - Etonogestrel), very effective likely <0.1%
Very rare risk of implant migration
15% bleeding irregularities
Not studied in overweight >130% IBW
Permanent contraception
Tubal Ligation - 0.15%
Vasectomy - 0.15%
Prescribing contraception
Start contraception if reasonably certain not pregnant
Pregnancy test >2w after last episode of unprotected intercourse
≤7d after start of normal menses or spontaneous/induced abortion
No sex since start of last normal menses
Correctly, consistently using reliable contraception
4w postpartum
Fully breastfeeding and <6 months postpartum
Back-up contraception for 7d if >7d after menses started
Special populations
Postpartum, breastfeeding, smokers >35 years old
Consider progestin-only
Medical comorbidities
Consider LARCs
>50 years old
Consider progestin-only or non-hormonal method (consider avoiding estrogen)
After amenorrhea x 12 months
No need for contraception if using non-hormonal method and >50yo (if <50yo advised to wait 2 years)
Consider FSH x 2 (>6 weeks apart) if >30IU/L then contraception required for another 12 months
>55 years old can discontinue contraception (even if menstrual cycles continue, spontaneous conception very unlikely)
Emergency contraception
Copper IUD - failure rate of <1% (>95% effective)
Effective up to 5 days (limited evidence up to 7 days) after unprotected intercourse, provided pregnancy ruled out
Hormonal/oral (less effective if BMI>30 or weight ≥80kg), side effects include headache, irregular bleeding , N/V
Ulipristal acetate 30mg PO x1 - failure rate of 1.4% (~75% effective)
Effective up to 5 days
Hormonal contraception can be initiated up to 5 days after unprotected sex with backup for first 14d
Levonorgestrel 1.5 mg PO x1 (or 0.75mg q12h x2) - failure rate of 2.2% (~50% effective)
Effective up to 72h (proven efficacy up to 96h, limited efficacy up to 120h)
Hormonal contraception can be initiated the day of (or after) with backup for first 7d
Combined OCP (Yuzpe) 100-120mcg ethinyl estradiol plus 500-600 mcg levonorgestrel (5 pills of Alesse) q12h x2 - least effective
Effective up to 72h
Note: Approx. 5% risk of pregnancy if unprotected sex, but up to 30% if 1-2d prior to ovulation
Only contraindications are pregnancy (and active pelvic infection/cervicitis for IUD)
Combined OCP
Efficacy
Failure rate
Perfect-use 0.3%
Typical-use 9%
Formulations
Mono vs multiphasic (no proven clinical advantage of multiphasic pills)
Estrogen (ethinyl estradiol)
Standard 30mcg (Marvelon, Yasmin), 35mcg (Ortho 1/35)
Low 25mcg (Tri-Cyclen Lo), 20mcg (Alesse)
Very Low 10mcg (Lo Loestrin Fe)
Progestins have both progestogenic and androgenic activity (newer selective progestins have no proven advantage and associated with possible higher risk of VTE)
First generation (Norethindrone acetate, Ethynodiol diacetate, Lynestrenol, Norethynodrel)
Second generation (dl-Norgestrel, Levonorgestrel)
Third generation (Desogestrel, Gestodene, Norgestimate)
Unclassified
Drosperinone
Cyproterone acetate (Diane) often prescribed for acne or hirsutism, but higher risk of VTE
Shorter pill-free interval, continuous pill
Seasonale or Seasonique (91-day cycle)
Lybrel 20mcg ethinyl estradiol/levonorgestrel 0.09mg
Break-through bleeding occurs early cycles, but decreases over time
Contraindications to Estrogen
Migraine with aura (≥5 min reversible visual/sensory/speech/motor symptom that is accompanied within 60 mins by a headache)
Smoker age ≥35 years and smoking ≥15 cigarettes per day
Uncontrolled hypertension (>160/100)
Acute DVT/PE
History of DVT/PE, not on anticogulation, with risk factor (history of estrogen-associated DVT/PE, pregnancy-associated DVT/PE, idiopathic DVT/PE, known thrombophilia including antiphospholipid syndrome/SLE, active cancer with the exception of non-melanoma skin cancer, history of recurrent DVT/PE)
Current or history of vascular disease, ischemic heart disease, stroke, complicated valvular disease (pulmonary hypertension, risk of atrial fibrillation, history of subacute bacterial endocarditis)
Liver disease (severe cirrhosis, hepatocellular adenoma, malignant hepatoma)
<4 weeks postpartum or peripartum cardiomyopathy
Major surgery with prolonged immobilization
Complicated solid organ transplantation (graft failure, cardiac allograft vasculopathy)
Active breast cancer
Note: Only contraindication to progestin-only pills is current breast cancer, relative contraindications include liver disease
Interactions with other medications
Decreased effectiveness with anticonvulsants (phenytoin, phenobarbitol), antiretrovirals, rifampin (not other antibiotics)
Side effects
Common in first three months, tend to improve with time
Nausea - Take pill at bedtime or with meal (consider lower estrogen)
Breast tenderness (consider lower estrogen)
Headache
Breakthrough bleeding (r/o smoking, noncompliance, cervical/uterine disease, pregnancy, consider increase estrogen)
No evidence of weight gain
Consider Progestin-only for Hypertension
Non-Contraceptive Benefits/Risks
Benefits
Cycle regulation, predictable bleeds
Decreased menstrual flow, anemia
Decreased acne, hirsutism
Decreased dysmenorrhea, premenstrual symptoms
Decreased perimenopausal symptoms
Decreased risk of fibroids, ovarian cyst
Risks
VTE RR 2-3 (compared to pregnancy RR 6 and postpartum RR 115)
10 / 10,000 woman-years (COC users) vs. 4-5 / 10,000 woman-years (non-users)
UNCLEAR risk of gallbladder disease, possible increase in symptomatic gallstones when used for 15 years
Other
NOT associated with increased risk of MI or CVA if no risk factors
NOT associated with increased risk of major birth defects if taken before/during pregnancy
Cancer
Decreased ovarian, endometrial, colorectal cancer
Possible association with cervical cancer (causation not demonstrated)
Decreased risk of benign breast disease
Possible increase in breast cancer in current/recent COC users
5 / 1000 COC-users vs. 4 / 1000 non-users will be diagnosed with breast cancer before 39 years-old
Follow-up
Weight (BMI), BP
Contraindications (Smoking, Migraines, Liver disease, Thromboembolic disease, Cardiovascular risk factors, Cancer)
Stop OCP at age 50yo, consider taper or switch to HRT if vasomotor symptoms
STI screen
Missed Combined OCP
If missed pill <24h in any week
Take most recent pill ASAP (even if it means two pills the same day) and continue taking remaining pills until end of pack
If missed pills in first week
Take most recent pill ASAP (even if it means two pills the same day) and continue taking remaining pills until end of pack
Back up x 7d*
If missed pills during second or third week
Take most recent pill ASAP (even if it means two pills the same day) and continue taking remaining pills until end of pack and start new cycle of OCP without a hormone-free interval
Back-up contraception if 3 or more consecutive doses/days of OCP missed
*if unprotected intercourse in last 5 days and not on active hormone x 7 consecutive days, there is a risk of ovulation and unintended pregnancy consider emergency contraception
Missed Combined Oral Contraceptive Pill
Missed Progestin only pills
>3h delay
Take most recent pill ASAP and continue taking remaining pills until end of pack
Back-up x 48h
If unprotected intercourse in last 5 days, EC recommended
References:
RACGP 2017. https://www.racgp.org.au/afp/2017/october/
FSRH 2017. Aged Over 40. https://www.fsrh.org/standards-and-guidance/current-clinical-guidance/contraception-for-specific-populations/
CUA 2016. https://www.cua.org/themes/web/assets/files/vasectomy4017_v4.pdf
CDC 2016. https://www.cdc.gov/mmwr/volumes/65/rr/pdfs/rr6504.pdf
CDC When to start. https://www.cdc.gov/reproductivehealth/contraception/pdf/when-to-start_508tagged.pdf
SOGC 2008. Missed Hormonal Contraceptives. https://sogc.org/wp-content/uploads/2013/01/gui219ECO0811.pdf